THE SYNTHESIS AND EVALUATION OF NEW CARBOCYCLIC PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS
- Authors
- Lee, Jongbok; Seo, Hyewon; Yoon, Sangeun; Choi, Kowoon; Lee, Chul-Hoon; Rhee, Hakjune
- Issue Date
- Jul-2014
- Publisher
- Elsevier BV
- Keywords
- TOYOCAMYCIN; ANTIBIOTICS; ANTIVIRAL AGENT CARBOVIR; HUMAN CYTOMEGALOVIRUS; EFFICIENT SYNTHESIS; TUBERCIDIN; PYRIMIDINES; SANGIVAMYCIN; CYTOTOXICITY; PI-ALLYLPALLADIUM COMPLEXES
- Citation
- Heterocycles, v.89, no.7, pp 1606 - 1619
- Pages
- 14
- Indexed
- SCI
SCIE
SCOPUS
- Journal Title
- Heterocycles
- Volume
- 89
- Number
- 7
- Start Page
- 1606
- End Page
- 1619
- URI
- https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/22396
- DOI
- 10.3987/COM-14-12999
- ISSN
- 0385-5414
1881-0942
- Abstract
- New carbocyclic pyrrolo[2,3-d]pyrimidine nucleoside analogs were synthesized with the key intermediate, 4-amino-6-bromo-5-cyanopyrrolo[2,3-c]pyrimidine (2), by S(N)2 reaction. One of the products, 4-amino-6-bromo-1-cyclopentyl-1H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (9), showed significant anti-proliferative activity to the human ovarian cancer PA-1 cells (IC50: 3.9 mu M). Based on the biological effects and the functional group characteristics of the compound 9, other carbocyclic nucleoside analogs related to the compound 9 were synthesized with key intermediate 2 by a Pd(0)-catalyzed coupling reaction. As expected, syn-4-amino-6-bromo-7[4-(methoxymethyl)-2-cyclopenten-1-yl]-17H-pyrrolo[2,3-d]pyrimidine-5-carboxamide (15) showed very similar antiproliferative activity (IC50: 2.6 mu M) when compared to compound 9.
- Files in This Item
-
Go to Link
- Appears in
Collections - COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY > DEPARTMENT OF CHEMICAL AND MOLECULAR ENGINEERING > 1. Journal Articles
- COLLEGE OF PHARMACY > DEPARTMENT OF PHARMACY > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/22396)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.